## Quantification of T2-FLAIR mismatch in non-enhancing diffuse gliomas using digital subtraction

(Supplement submitted to American Journal of Neuroradiology)

Nicholas S. Cho<sup>1-4</sup>, Francesco Sanvito<sup>1,2</sup>, Viên Lam Le<sup>1-3</sup>, Sonoko Oshima<sup>1,2</sup>, Ashley Teraishi<sup>1,2</sup>,

Jingwen Yao<sup>1,2</sup>, Donatello Telesca<sup>5</sup>, Catalina Raymond<sup>1,2</sup>, Whitney B. Pope<sup>2</sup>, Phioanh L.

Nghiemphu<sup>6,7</sup>, Albert Lai<sup>6,7</sup>, Timothy F. Cloughesy<sup>6,7</sup>, Noriko Salamon<sup>2</sup>,

Benjamin M. Ellingson<sup>1-3, 8, 9, ¥</sup>

<sup>1</sup>UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging

Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA

<sup>2</sup> Department of Radiological Sciences, David Geffen School of Medicine, University of

California, Los Angeles, Los Angeles, CA, USA

<sup>3</sup> Department of Bioengineering, Henry Samueli School of Engineering and Applied Science,

University of California, Los Angeles, Los Angeles, CA, USA

<sup>4</sup> Medical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

<sup>5</sup> Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA

<sup>6</sup> UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

<sup>7</sup> Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA <sup>8</sup> Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

<sup>9</sup> Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine,

University of California, Los Angeles, Los Angeles, CA, USA

<sup>¥</sup>Corresponding author

Benjamin M. Ellingson, Ph.D.

Director, UCLA Brain Tumor Imaging Laboratory (BTIL)

Professor of Radiology, Psychiatry, and Neurosurgery

Departments of Radiological Sciences, Psychiatry, and Neurosurgery

David Geffen School of Medicine

University of California, Los Angeles

924 Westwood Blvd., Suite 615

Los Angeles, CA 90024 (bellingson@mednet.ucla.edu)

Phone: 310-481-7572

Fax: 310-794-2796

## Supplementary Tables

Supplementary Table 1. Contingency tables of percentage T2-FLAIR mismatch volume and

tumor grade in IDH-mutant astrocytomas.

≥25% T2FM-Volume IDHm-A Distribution Across Cohorts					
	<25% T2FM-Volume	≥25% T2FM-Volume	Fisher's Exact		
	IDHm-A	IDHm-A	p-value		
TCIA	31	15	<i>P</i> =0.03		
INST	7	12	-		
Tumor Grade Distrib	ution Across Cohorts	1			
	IDHm-A Grade 2	IDHm-A Grade 3-4	Fisher's Exact		
			p-value		
TCIA	33	13	<i>P</i> =0.38		
INST	11	8	-		
TCIA: Tumor Grade	Distribution Based on 25	% T2FM-Volume			
	IDHm-A Grade 2	IDHm-A Grade 3-4	Fisher's Exact		
			p-value		
<25% T2FM-Volume	24	7	<i>P</i> =0.30		
≥25% T2FM-Volume	9	6	-		
INST: Tumor Grade I	Distribution Based on 25%	% T2FM-Volume			
	IDHm-A Grade 2	IDHm-A Grade 3-4	Fisher's Exact		
			p-value		
<25% T2FM-Volume	6	1	P=0.15		

≥25% T2FM-Volume	5	7	

IDHm-A = isocitrate dehydrogenase mutant astrocytoma; TCIA = The Cancer Imaging Archive

cohort; INST = institutional cohort

**Supplementary Table 2.** Pooled diagnostic performance of quantitative percentage T2-FLAIR mismatch volume and reader assessment of T2-FLAIR mismatch sign for classifying IDH-mutant astrocytoma.

Classification Definition	Sensitivity	Specificity	
≥42% T2FM-volume	23.1%	100%	
≥25% T2FM-volume	41.5%	95%	
≥15% T2FM-volume	50.8%	90%	
Patel <i>et al.</i> <sup>1</sup>	30.8–38.5%	92.5–97.5%	
(Reader min-max)			
Lasocki <i>et al.</i> <sup>2</sup>	41.5–55.4%	85.0-92.5%	
(Reader min-max)			

T2FM = T2-FLAIR mismatch

## **Supplementary Figures**



Supplementary Figure 1. Patient selection flowchart. TCIA = The Cancer Imaging Archive;

IDH = isocitrate dehydrogenase



[TCIA] ROC of % T2FM-Volume for IDHm-A Classification (<1% Rounded to 0%)



IDHm-A Classification (<5% Rounded to 0%)

[TCIA] ROC of % T2FM-Volume for



[INST] ROC of % T2FM-Volume for IDHm-A Classification (<1% Rounded to 0%)



[INST] ROC of % T2FM-Volume for IDHm-A Classification (<5% Rounded to 0%)



[Pooled] ROC of % T2FM for IDHm-A Classification (<1% Rounded to 0%)



[Pooled] ROC of % T2FM for IDHm-A Classification (<5% Rounded to 0%)



Supplementary Figure 2. Assessment of finite image misregistration and empiric "noise floors" of % T2-FLAIR mismatch volume on T2-FLAIR subtraction maps. (A) Finite 2 mm posterior translation or 2 degree counter-clockwise rotation misregistration resulted in an average magnitude difference of 1.04% T2-FLAIR mismatch (T2FM)-volume. In subsequent ROC curve analyses, (B) AUC in the TCIA cohort was 0.664 and (C) 0.660 for classifying IDH mutant astrocytoma when considering a <1% = 0% T2FM-volume and a <5% = 0% T2FM-volume noise floor, respectively. In the institutional cohort, (D) AUC was 0.919 and (E) 0.890 for classifying IDH mutant astrocytoma when considering a <1% = 0% T2FM-volume and a <5% = 0% T2FM-volume noise floor, respectively. In the pooled cohort, (F) AUC was 0.720 and (G) 0.718 for classifying IDH mutant astrocytoma when considering a <1% = 0% T2FM-volume and a <5% = 0% T2FM-volume and a <5% = 0% T2FM-volume and a <5% = 0% T2FM-volume noise floor, respectively. In the pooled cohort, (F) AUC was 0.720 and (G) 0.718 for classifying IDH mutant astrocytoma when considering a <1% = 0% T2FM-volume and a <5% = 0%

TCIA = The Cancer Imaging Archive; INST = Institutional; ROC = Receiver-operating characteristic; AUC = Area under curve; T2FM = T2-FLAIR mismatch



Supplementary Figure 3. Differences in T2-FLAIR non-mismatch thickness in IDH-mutant astrocytomas grouped by % T2-FLAIR mismatch volume. T2-FLAIR non-mismatch (T2FNM)-subregion thickness was significantly different across 15–25% T2-FLAIR mismatch (T2FM)-volume, 25–42% T2FM-volume, and  $\geq$ 42% T2FM-volume IDH mutant astrocytoma (IDHm-A) in the TCIA (A: *P*=0.001) and institutional cohorts (B: *P*=0.001). Post-hoc tests showed that  $\geq$ 42% T2FM-volume IDHm-A had significantly thinner T2FNM subregions compared to 15–25% T2FM-volume IDHm-A in the TCIA (A: *P*=0.007) and institutional cohorts (B: *P*=0.01).

IDHm-A = Isocitrate dehydrogenase mutant astrocytoma; TCIA = The Cancer Imaging Archive; INST = Institutional; T2FM = T2-FLAIR Mismatch; \* indicates P < 0.05, \*\* indicates P < 0.01



Supplementary Figure 4. Assessment of patient age and sex with percentage T2-FLAIR mismatch volume. There were no significant relationships in age (A/C) or sex (B/D) with %T2FM-volume in either cohort. IDHm-A = Isocitrate dehydrogenase mutant astrocytoma; TCIA = The Cancer Imaging Archive;

INST = Institutional; T2FM = T2-FLAIR Mismatch;

## References

 Patel SH, Poisson LM, Brat DJ, et al. T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. *Clinical Cancer Research* 2017;23:6078-6085

 Lasocki A, Buckland ME, Drummond KJ, et al. Conventional MRI features can predict the molecular subtype of adult grade 2–3 intracranial diffuse gliomas. *Neuroradiology* 2022;64:2295-2305